ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to with your ASCO member or guest account, and visit the subscription center available under your account profile.

Tune in to ASCO's new ASCO in Action podcast series, providing analysis and commentary on cancer policy and practice issues, available through iTunes or Google Play.

Showing results for Cancer Research

October 19, 2018

ASCO and the Society for Immunotherapy of Cancer (SITC) have released a joint statement with twelve clinical trial reporting recommendations that address the unique efficacy, toxicity, and combination/sequencing aspects of immune-oncology (IO) treatments. These recommendations, jointly published in Journal of Clinical Oncology (JCO) and Journal for ImmunoTherapy of Cancer (JITC), will lead to better IO trial reporting and assessment.

October 18, 2018

Richard L. Schilsky, MD, FACP, FSCT, FASCO, Senior Vice President and Chief Medical Officer of ASCO will moderate a panel at an upcoming public meeting of the Reagan-Udall Foundation for the Food and Drug Administration (FDA) on November 19, 2018, at the FDA main campus at White Oak.

October 2, 2018

ASCO is assembling a cohort of its members who are willing to participate in survey-based research projects of ASCO members for non-commercial purposes. The immense knowledge and experience of ASCO’s membership can help to accelerate the development of new insights and findings that may help to improve care and care delivery.

September 28, 2018

The ASCO Research Community Forum (RCF) 2018 Annual Meeting brought together 159 physician investigators and research staff from 34 states across the country—its largest meeting to-date—to discuss contemporary challenges and develop creative solutions in conducting and managing clinical trials. The meeting, held annually at ASCO's headquarters in the Washington DC Metro area, spanned two days from September 23-24, with a theme of Innovative Solutions. Best Practices. Excellence in Cancer Research.

September 26, 2018

ASCO applauds Congress for passing a $2 billion increase in funding for the National Institutes of Health (NIH), which will bring NIH's budget to a total of $39.1 billion and the National Cancer Institute's to a total of $6.147 billion.

September 13, 2018

A new study in the Journal of Oncology Practice surveys practices within ASCO’s Quality Oncology Practice Initiative (QOPI®) to learn about real world implementation and use of Patient Reported Outcomes (PROs). The survey yielded valuable information on the perception of PROs among oncology practices and the data currently being collected.

September 13, 2018

The American Society of Clinical Oncology (ASCO) today issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials. ASCO’s policy statement, “Addressing Financial Barriers to Patient Participation in Clinical Trials,” stresses the importance of increasing participation in clinical research, especially for patients from particular ethnic/racial, geographic, age, socioeconomic, and other underserved demographic subgroups.

August 31, 2018

A new Quality in Action study in the Journal of Oncology Practice (JOP) outlines a successful effort to improve appointment scheduling for patients participating in clinical trials. The methodology of this project can be utilized to evaluate and optimize other processes and units within cancer centers outside of scheduling.

August 22, 2018

CancerLinQ LLC, a wholly-owned nonprofit subsidiary of the ASCO, has brought on technology collaborators Concerto HealthAI and Tempus to accelerate its joint research effort with the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) aimed at understanding the real-world use, tolerability, and effectiveness of immune checkpoint inhibitors. Concerto HealthAI and Tempus have begun to assist in the analysis of a de-identified data set that CancerLinQ has provided to the FDA, representing more than 10,000 patients who have been treated with immune checkpoint inhibitors for both approved and unapproved indications.

August 16, 2018

Citizens around the country have an open invitation to host their own events in their communities with support and resources offered by the Biden Cancer Initiative in conjunction with the National Biden Cancer Summit to be held on September 21 in Washington, D.C. 

July 27, 2018

On July 25, the U.S. House Energy and Commerce Committee held a hearing during which Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, Director of the National Cancer Institute (NCI) Norman Sharpless, MD, and Director of National Institutes of Health Francis Collins, MD, PhD, provided updates on how their respective agencies have been implementing the 21st Century Cures legislation.

July 5, 2018

ASCO and the European Society for Medical Oncology (ESMO), are calling on leaders and health ministers of the 193 United Nations (UN) member countries to reduce the burden of all non-communicable diseases (NCDs), including cancer. The two organizations issued a joint statement in advance of the third High-level Meeting of the United Nations (UN) General Assembly on the Prevention and Control of NCDs, taking place on September 27, 2018, in New York.

June 26, 2018

In the latest ASCO in Action Podcast, Dr. Edward Kim, Chair of the Department of Solid Tumor Oncology at the Levine Cancer Institute, joined ASCO CEO Dr. Clifford A. Hudis to discuss eligibility criteria for cancer clinical trials.

June 20, 2018

The Department of Health and Human Services (HHS) has announced further delay for implementation of the updated Common Rule until January 2, 2019.

June 19, 2018

The Journal of Oncology Practice (JOP) launched a new care delivery blog, JOP DAiS (Discussion & Analysis in Short), to serve as a forum for commentary and analysis on issues affecting the mechanisms of oncology care delivery. This new platform will be a way to collaborate, debate, and discuss many of the topics JOP addresses in its publication including health services research, business and socioeconomics, ethics, and health policy.